Evaluation of Vaginal Laxity and Bladder Neck Descent in Parous Women Using 2D and 3D Transperineal Ultrasound (VLBNDUS)

March 19, 2026 updated by: Ola Abd El Hares Mahros Ali, Assiut University
This study aims to evaluate vaginal laxity and bladder neck descent in women who have given birth, using non-invasive 2D and 3D transperineal ultrasound. Participants will complete a short questionnaire about pelvic floor symptoms and undergo a pelvic examination. The ultrasound will measure bladder neck position, levator hiatus dimensions, and related pelvic floor structures at rest and during straining. The study will compare findings between women with previous vaginal deliveries and those who had cesarean sections. Participation is voluntary, and all procedures are safe, non-invasive, and similar to routine clinical practice. The results will help better understand pelvic floor changes after childbirth and may improve the management of pelvic floor disorders.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

Pelvic floor dysfunction is a common condition affecting women after childbirth, often resulting in vaginal laxity, bladder neck descent, and related pelvic floor symptoms such as urinary incontinence and sexual dysfunction. This observational cross-sectional study will assess 185 parous women, aged 18 years or older, using both 2D and 3D transperineal ultrasound. Participants will complete the Pelvic Floor Distress Inventory-20 questionnaire and undergo a pelvic examination using the POP-Q system after bladder emptying. Ultrasound measurements will include bladder neck height, retrovesical angle, levator hiatal dimensions, levator ani muscle integrity, and other related parameters at rest and during Valsalva maneuver. Women will be categorized based on mode of delivery (vaginal vs cesarean) and results will be analyzed to determine correlations between pelvic floor anatomy and symptom severity. The study aims to provide a comprehensive understanding of pelvic floor alterations in parous women, which may inform clinical assessment and management strategies for pelvic floor dysfunction.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
185

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Ola Abd El Hares Mahros Ali resistant Obstetrics & Gynecology Department Assiut University
  • Phone Number: 01158002972
  • Email: drola6181@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population consists of parous women attending the Women's Health Hospital, Urogynecology and Advanced Ultrasound units. Participants will include women with at least one vaginal delivery or only cesarean deliveries, aged 18 years or older. They will be recruited to assess pelvic floor function and anatomical changes using 2D and 3D transperineal ultrasound.

Description

Inclusion Criteria:

  • Parous women aged 18 years or older
  • Willing to provide informed consent
  • Able to complete the Pelvic Floor Distress Inventory-20 questionnaire
  • Undergo 2D and 3D transperineal ultrasound and POP-Q examination

Exclusion Criteria:

  • Pregnant women
  • History of previous prolapse surgery
  • Patients with neurological disorders affecting pelvic floor function

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Vaginal Delivery (VD)
Women who have had at least one vaginal delivery. Participants will undergo pelvic floor evaluation including 2D and 3D transperineal ultrasound, complete the Pelvic Floor Distress Inventory-20 questionnaire, and undergo POP-Q clinical examination. No therapeutic interventions are assigned.
Cesarean Section (CS)
Women who have had only cesarean deliveries. Participants will undergo pelvic floor evaluation including 2D and 3D transperineal ultrasound, complete the Pelvic Floor Distress Inventory-20 questionnaire, and undergo POP-Q clinical examination. No therapeutic interventions are assigned.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Levator Hiatal Area
Time Frame: Measured once during ultrasound assessment after bladder emptying
Levator hiatal area will be measured using 2D and 3D transperineal ultrasound in the midsagittal plane. Measurements will be taken at rest and during maximal Valsalva maneuver to assess pelvic floor anatomy in parous women and compare between vaginal delivery and cesarean section groups.
Measured once during ultrasound assessment after bladder emptying

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 19, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 19, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 24, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 24, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 19, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • VaginalLaxity_US_2026

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings